Nifurtimox is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Not commercially available in the U.S.
- Available from the CDC under investigational protocols. Drug can be obtained by callingParasitic Diseases Public Inquiries (404-718-4745; e-mail chagas@cdc.gov). Outside of regular business hours call the CDC Emergency Operations Center (770-488-7100) and ask for the person on call for parasitic diseases.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- American trypanosomiasis (Chagas’ disease, T. cruzi): acute early phase of the disease.
- May be used in combination with eflornithine for the treatment of second-stage sleeping sickness.
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: June 7, 2017
Citation
* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Nifurtimox
ID - 540385
A1 - Avdic,Edina,Pharm.D.
AU - Pham,Paul,Pharm.D.
Y1 - 2017/06/07/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540385/all/Nifurtimox
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -